Here’s what you should know:
1. The company is in the process of validating two clinical trials, in an attempt to earn a CE Mark.
2. If successful, the company plans to launch a frontline CRC screening product sometime in 2018.
3. Volition’s CEO Cameron Reynolds said in a release the product launch will be the company’s “largest near-term opportunity.” He added the European market has 150 million-plus residents of screening age.
4. Volition is in the midst of a U.S.-based study as well. The company is conducting a 13,500 patient study with the Early Detection Research Network and Rockville, Md.-based U.S. National Cancer Institute.
More articles on gastroenterology:
GI leader to know: Dr. Francis Farraye of Boston Medical Center
Stock market week-in-review for 5 large GI companies — Sept. 11-15
Patient engagement, case conference less effective in IBD care than perceived
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
